BLOG

OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

Collaborating with the German family-controlled drug maker on OSE’s novel checkpoint inhibitor aligns with French firm’s strategy of partnering its portfolio candidates.